Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma

Acta Neuropathologica

Volumn 128, Issue 4, 2014, Pages 551-559

  Sahm, Felix ^a,b   Reuss, David ^a,b   Koelsche, Christian ^a,b   Capper, David ^a,b   Schittenhelm, Jens ^c   Heim, Stephanie ^d   Jones, David T W ^b   Pfister, Stefan M ^b,e   Herold Mende, Christel ^e   Wick, Wolfgang ^b,e   Mueller, Wolf ^f   Hartmann, Christian ^g   Paulus, Werner ^d   von Deimling, Andreas ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^f UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^g HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

1p 19q; ATRX; IDH1; Mixed glioma; Oligoastrocytoma; TP53

Indexed keywords

PROTEIN P53; ATRX PROTEIN, HUMAN; DNA HELICASE; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; NUCLEAR PROTEIN;

ARTICLE; ASTROCYTOMA; ATRX GENE; CANCER RADIOTHERAPY; CANCER SURGERY; CELL NUCLEUS; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; CLINICAL ARTICLE; GENE; GENE MUTATION; GENETIC MARKER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IDH1 GENE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MOLECULAR GENETICS; OLIGODENDROGLIOMA; PROTEIN DEPLETION; TISSUE SECTION; TP53 GENE; TUMOR CLASSIFICATION; BRAIN TUMOR; CHROMOSOME 1; CHROMOSOME 19; CLASSIFICATION; FEMALE; GENETICS; MALE; MOLECULAR BIOLOGY; MUTATION; RETROSPECTIVE STUDY;

ASTROCYTOMA; BRAIN NEOPLASMS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; DNA HELICASES; FEMALE; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MOLECULAR BIOLOGY; MUTATION; NUCLEAR PROTEINS; OLIGODENDROGLIOMA; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84919921568     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-014-1326-7     Document Type: Article

References (46)

1. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116:597–602
2. Bo H, Ghazizadeh M, Shimizu H et al (2004) Effect of ionizing irradiation on human esophageal cancer cell lines by cDNA microarray gene expression analysis. J Nippon Med Sch Nippon Ika Daigaku zasshi 71:172–180
3. Boiardi A, Silvani A, Pozzi A et al (1997) Advantage of treating anaplastic gliomas with aggressive protocol combining chemotherapy and radiotherapy. J Neurooncol 34:179–185
4. Burger PC, Minn AY, Smith JS et al (2001) Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections. Mod Pathol Off J US Can Acad Pathol Inc 14:842–853
5. Cairncross G, Wang M, Shaw E et al (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol Off J Am Soc Clin Oncol 31:337–343
6. Camelo-Piragua S, Jansen M, Ganguly A, Kim JC, Louis DN, Nutt CL (2010) Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis. Acta Neuropathol 119:509–511
7. Capper D, Sahm F, Hartmann C (2010) Application of mutant IDH1 antibody to differentiate diffuse glioma from non-neoplastic central nervous system lesions and therapy induced changes. Am J Surg Pathol 34:1199–1204
8. Capper D, Weissert S, Balss J et al (2010) Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 20:245–254
9. Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A (2009) Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 118:599–601
10. Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK (1997) Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79:1381–1393
11. Cooper ERA (1935) The relation of oligocytes and astrocytes in cerebral tumours. J Pathol Bacteriol 41:259–266
12. Daumas-Duport C, Varlet P, Tucker ML, Beuvon F, Cervera P, Chodkiewicz JP (1997) Oligodendrogliomas. Part I: patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases. J Neurooncol 34:37–59
13. Devaux BC, O’Fallon JR, Kelly PJ (1993) Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. J Neurosurg 78:767–775
14. Fuller CE, Schmidt RE, Roth KA et al (2003) Clinical utility of fluorescence in situ hybridization (FISH) in morphologically ambiguous gliomas with hybrid oligodendroglial/astrocytic features. J Neuropathol Exp Neurol 62:1118–1128
15. Hart MN, Petito CK, Earle KM (1974) Mixed gliomas. Cancer 33:134–140
16. Hartmann C, Meyer J, Balss J et al (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118:469–474
17. Henson JW, Hobbs W, Chakravarti A, Louis DN (2005) Alterations in p53, p21, and MIB-1 labeling index in primary human astrocytomas following radiation therapy. J Neurooncol 74:151–154
18. Jiao Y, Killela PJ, Reitman ZJ et al (2012) Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 3:709–722
19. Kannan K, Inagaki A, Silber J et al (2012) Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget 3:1194–1203
20. Lammie GA, Beckett A, Courtney R, Scaravilli F (1994) An immunohistochemical study of p53 and proliferating cell nuclear antigen expression in progressive multifocal leukoencephalopathy. Acta Neuropathol 88:465–471
21. Lass U, Hartmann C, Capper D et al (2013) Chromogenic in situ hybridization is a reliable alternative to fluorescence in situ hybridization for diagnostic testing of 1p and 19q loss in paraffin-embedded gliomas. Brain Pathol 23:311–318
22. Lass U, Numann A, von Eckardstein K et al (2012) Clonal analysis in recurrent astrocytic, oligoastrocytic and oligodendroglial tumors implicates IDH1-mutation as common tumor initiating event. PLoS One 7:e41298
23. Liu XY, Gerges N, Korshunov A et al (2012) Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol 124:615–625
24. Louis DN (1994) The p53 gene and protein in human brain tumors. J Neuropathol Exp Neurol 53:11–21
25. Louis DN, Cavenee WK, Ohgaki H, Wiestler OD (2007) WHO classification of tumours of the central nervous system. World Health Organization, Lyon
26. Louis DN, von Deimling A, Chung RY et al (1993) Comparative study of p53 gene and protein alterations in human astrocytic tumors. J Neuropathol Exp Neurol 52:31–38
27. Maintz D, Fiedler K, Koopmann J et al (1997) Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol 56:1098–1104
28. Mueller W, Hartmann C, Hoffmann A et al (2002) Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol 161:313–319
29. Nguyen DN, Heaphy CM, de Wilde RF et al (2013) Molecular and morphologic correlates of the alternative lengthening of telomeres phenotype in high-grade astrocytomas. Brain Pathol 23:237–243
30. Perry A (2001) Oligodendroglial neoplasms: current concepts, misconceptions, and folklore. Adv Anat Pathol 8:183–199
31. Pusch S, Sahm F, Meyer J, Mittelbronn M, Hartmann C, von Deimling A (2010) Glioma IDH1 mutation patterns off the beaten track. Neuropathol Appl Neurobiol 37:428–430
32. Qu M, Olofsson T, Sigurdardottir S et al (2007) Genetically distinct astrocytic and oligodendroglial components in oligoastrocytomas. Acta Neuropathol 113:129–136
33. Rubio MP, von Deimling A, Yandell DW, Wiestler OD, Gusella JF, Louis DN (1993) Accumulation of wild type p53 protein in human astrocytomas. Cancer Res 53:3465–3467
34. Sahm F, Koelsche C, Meyer J et al (2012) CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas. Acta Neuropathol 123:853–860
35. Schwartzentruber J, Korshunov A, Liu XY et al (2012) Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482:226–231
36. Shaw EG, Scheithauer BW, O’Fallon JR, Davis DH (1994) Mixed oligoastrocytomas: a survival and prognostic factor analysis. Neurosurgery 34:577–582 (discussion 582)
37. Sturm D, Witt H, Hovestadt V et al (2012) Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22:425–437
38. Ueki K, Nishikawa R, Nakazato Y et al (2002) Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. Clin Cancer Res Off J Am Assoc Cancer Res 8:196–201
39. van den Bent MJ, Brandes AA, Taphoorn MJ et al (2013) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol Off J Am Soc Clin Oncol 31:344–350
40. Watanabe T, Nakamura M, Kros JM et al (2002) Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas. Acta Neuropathol 103:267–275
41. Wick W, Hartmann C, Engel C et al (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol Off J Am Soc Clin Oncol 27:5874–5880
42. Wiestler B, Capper D, Holland-Letz T et al (2013) ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol 126:443–451
43. Wiestler B, Capper D, Sill M et al (2014) Integrated DNA methylation and copy-number profiling identifies three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathologica (in press)
44. Wiestler B, Capper D, Volker Hovestadt V et al (2014) Assessing CpG island methylator phenotype, 1p/19q codeletion and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. Neuro Oncol (in press)
45. Wolter M, Reifenberger J, Blaschke B et al (2001) Oligodendroglial tumors frequently demonstrate hypermethylation of the CDKN2A (MTS1, p16INK4a), p14ARF, and CDKN2B (MTS2, p15INK4b) tumor suppressor genes. J Neuropathol Exp Neurol 60:1170–1180
46. Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773